Abstract
AMP-activated protein kinase (AMPK) is an enzyme that works as a fuel gauge, being activated in situations of high-energy phosphate depletion. Upon activation, AMPK functions to restore cellular ATP by modifying diverse metabolic pathways. AMPK is activated robustly by skeletal muscle contraction and myocardial ischemia, and may be involved in the stimulation of glucose transport and fatty acid oxidation produced by these stimuli. In liver, activation of AMPK results in enhanced fatty acid oxidation and in decreased production of glucose, cholesterol, and triglycerides. Recent studies have shown that AMPK is the cellular mediator for many of the metabolic effects of drugs such as metformin and thiazolidinediones, as well as the insulin sensitizing adipocytokines leptin and adiponectin. These data, along with evidence from studies showing that chemical activation of AMPK in vivo with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) improves blood glucose concentrations and lipid profiles, make this enzyme an attractive pharmacological target for the treatment of type 2 diabetes and other metabolic disorders.
Keywords: AMPK, ACC, exercise, glucose transport, type 2 diabetes mellitus
Current Medicinal Chemistry
Title: AMP-Activated Protein Kinase and Type 2 Diabetes
Volume: 13 Issue: 5
Author(s): Nicolas Musi
Affiliation:
Keywords: AMPK, ACC, exercise, glucose transport, type 2 diabetes mellitus
Abstract: AMP-activated protein kinase (AMPK) is an enzyme that works as a fuel gauge, being activated in situations of high-energy phosphate depletion. Upon activation, AMPK functions to restore cellular ATP by modifying diverse metabolic pathways. AMPK is activated robustly by skeletal muscle contraction and myocardial ischemia, and may be involved in the stimulation of glucose transport and fatty acid oxidation produced by these stimuli. In liver, activation of AMPK results in enhanced fatty acid oxidation and in decreased production of glucose, cholesterol, and triglycerides. Recent studies have shown that AMPK is the cellular mediator for many of the metabolic effects of drugs such as metformin and thiazolidinediones, as well as the insulin sensitizing adipocytokines leptin and adiponectin. These data, along with evidence from studies showing that chemical activation of AMPK in vivo with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) improves blood glucose concentrations and lipid profiles, make this enzyme an attractive pharmacological target for the treatment of type 2 diabetes and other metabolic disorders.
Export Options
About this article
Cite this article as:
Musi Nicolas, AMP-Activated Protein Kinase and Type 2 Diabetes, Current Medicinal Chemistry 2006; 13 (5) . https://dx.doi.org/10.2174/092986706776055724
DOI https://dx.doi.org/10.2174/092986706776055724 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Aesthetic Cardiology: Adipose-Derived Stem Cells for Myocardial Repair
Current Stem Cell Research & Therapy Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Cardiovascular & Hematological Disorders-Drug Targets A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Endogenous Cardiotonics: Search and Problems
Cardiovascular & Hematological Disorders-Drug Targets Tocotrienols and Cardiovascular Health
Current Pharmaceutical Design Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Precision Percutaneous Coronary Intervention of a Complex Lesion
Reviews on Recent Clinical Trials Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Good at Heart: Preserving Cardiac Metabolism during aging
Current Diabetes Reviews Microbial Transformation of Triterpenoids
Mini-Reviews in Organic Chemistry Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy